Vasoconstriction

Vasoconstriction is the narrowing of blood vessels caused by contraction of arterial smooth muscle.

As a drug effect it is acute and dose-proportional, easing as the substance wears off, which distinguishes it from clinical vascular conditions such as Raynaud's disease. It ranges from mild coldness in the extremities and a modest rise in blood pressure to severe circulatory restriction that can deprive tissues of oxygen.

Vasoconstriction is a common adverse effect across several drug classes. It is most commonly induced at moderate to high doses under stimulants such as amphetamine, MDMA, and cocaine, and under psychedelics such as LSD, 1B-LSD, and 1P-LSD. It also appears under synthetic cannabinoids such as THJ-018, JWH-018, and 5F-AKB48, and in a more variable form under depressants including GHB, GBL, and poppers.

Vasoconstriction is felt as a tightening and coldness spreading inward from the extremities: the hands and feet grow cold and may pale or blue at the fingertips, a pressured, pounding sensation builds at the temples and behind the eyes, and the face can feel flushed and taut.

The chest may seem constricted. Attending to these sensations — checking finger color, tracking the pulse — tends to heighten the perceived severity. At higher doses, particularly under stimulants and synthetic cannabinoids, the cold in the extremities can deepen toward numbness and an unsettling sense of diminished circulation.

Vasoconstriction arises through different pathways depending on the drug class:

• Stimulants — release or block reuptake of norepinephrine; the resulting alpha-adrenergic activation contracts arterial smooth muscle directly and potently.
• Psychedelics — act at serotonin receptor subtypes expressed in vascular tissue, producing constriction in peripheral and cranial vessels.
• Synthetic cannabinoids — interact with CB1 and CB2 receptors in ways that disrupt vascular tone; the mechanism is less well characterized than for other classes.
• Depressants — GHB and GBL can alter vascular tone at higher doses; poppers, though primarily vasodilating, may contribute to rebound constriction as their effects resolve.

How much each pathway contributes in a given case is not fully understood.

Who experiences it, and how strongly, varies widely. Higher doses raise both the likelihood and intensity substantially. Pre-existing cardiovascular conditions — hypertension, Raynaud's phenomenon, or coronary disease — amplify the response, as do cold ambient temperature, dehydration, and concurrent stimulant use.

Expectation plays a smaller role here than in psychologically mediated effects, but focusing on the physical sensations can heighten perceived severity. Tolerance to the vasoconstrictive effect may develop partially with repeated stimulant exposure, though underlying vascular risk does not diminish.